Skip to main content

Table 1 Clinical features of T-ALL patients in the Training and Validation Cohorts

From: Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study

 

Training cohort (n = 50)

Validation cohort (n = 34)

 

CCR (n = 28)

Relapse (n = 22)

CCR (n = 25)

Relapse (n = 9)

Sex

   Male/Female

21/7

21/1

14/11

9/0

Age at diag (years)

   Median (Range)

13.1 (2.1-16.9)

12.1 (1.8-17.8)

7.1 (2.2-18.3)*

8.8 (1.8-17.5)

WBC (×10 9 /L)

   Median (Range)

171.9 (1.1-791)

219.2 (4.9-700)

113.1 (8.2-524.4)

161.8 (13.4-882)

BM blast at diag (%)

   Median (Range)

94 (70-100)

91 (74-99)

90 (35-99)

95 (70-99)

Cytogenetics

   Normal (46 C)

2

3

13

4

   Pseudodiploid (46 C)

12

6

5

2

   Hyperdiploid (>47 C)

3

2

3

0

   Hypodiploid (<46 C)

0

0

2

1

   N/A

11

11

2

2

NCI Risk

   Standard

0

0

6

1

   High

28

22

19

8

Induction result

   M1

25

19

24

8

   M2

3

0

0

0

   M3

0

0

0

0

   N/A

0

3

1

1

Follow-up time (years)

   Median (Range)

7.3 (3.3-9.2)

 

8.8 (4.3-11.9)

 

Time to relapse (years)

   Median (Range)

 

1.3 (0.2-3.8)

 

1.4 (0.5-3.3)

  1. WBC, white blood cell count; BM, bone marrow; diag, diagnosis; C, chromosomes; N/A, not available; NCI, National Cancer Institute; M1, <5%blasts in BM; M2, 5-25% blasts in BM; M3, >25% blasts in BM. *P = 0.0082 by Mann-Whitney t-test compared to CCR in the training cohort.
Back to article page